Recent Advances in Biocatalysis for Drug Synthesis

Biomedicines

Alina Kinner¹  Stephan Lütz¹  Philipp Nerke¹  Katrin Rosenthal¹  Regine Siedentop¹  Jörg Pietruszka²  Thomas Classen²  Till Steinmetz³  Markus Nett³ 

[1] Chair for Bioprocess Engineering, Department of Biochemical and Chemical Engineering, TU Dortmund University, 44227 Dortmund, Germany;Institute of Bio- and Geosciences: Biotechnology (IBG-1), Forschungszentrum Jülich, 52428 Jülich, Germany;Laboratory for Technical Biology, Department of Biochemical and Chemical Engineering, TU Dortmund University, 44227 Dortmund, Germany;

关键词: biotransformation;    active pharmaceutical ingredient (API);    drug discovery;    nonribosomal peptide synthesis;    protein engineering;    scaffold forming;   

DOI  :  10.3390/biomedicines10050964

来源: DOAJ

【 摘 要 】

Biocatalysis is constantly providing novel options for the synthesis of active pharmaceutical ingredients (APIs). In addition to drug development and manufacturing, biocatalysis also plays a role in drug discovery and can support many active ingredient syntheses at an early stage to build up entire scaffolds in a targeted and preparative manner. Recent progress in recruiting new enzymes by genome mining and screening or adapting their substrate, as well as product scope, by protein engineering has made biocatalysts a competitive tool applied in academic and industrial spheres. This is especially true for the advances in the field of nonribosomal peptide synthesis and enzyme cascades that are expanding the capabilities for the discovery and synthesis of new bioactive compounds via biotransformation. Here we highlight some of the most recent developments to add to the portfolio of biocatalysis with special relevance for the synthesis and late-stage functionalization of APIs, in order to bypass pure chemical processes.

【 授权许可】

Unknown